U.S. Markets open in 8 hrs 23 mins

United Therapeutics Corporation (UTHR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
122.78+0.68 (+0.56%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close122.10
Open123.10
Bid0.00 x 800
Ask0.00 x 1200
Day's Range121.85 - 123.87
52 Week Range75.58 - 127.79
Volume382,972
Avg. Volume320,845
Market Cap5.453B
Beta (5Y Monthly)0.71
PE Ratio (TTM)12.58
EPS (TTM)9.76
Earnings DateOct 28, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est144.40
  • United Therapeutics Highlights Poster Presentations from the Recent CHEST 2020 Meeting
    PR Newswire

    United Therapeutics Highlights Poster Presentations from the Recent CHEST 2020 Meeting

    United Therapeutics Corporation (Nasdaq: UTHR) today announced new clinical data on Tyvaso® (treprostinil) Inhalation Solution in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) at CHEST 2020, the annual meeting of the American College of Chest Physicians, held October 18-21. The presentation featured safety data from the phase 3 INCREASE study of Tyvaso, which showed that patients with PH-ILD receiving Tyvaso, compared to those receiving placebo, experienced fewer exacerbations of underlying lung disease and an improvement in forced vital capacity (FVC). The data were featured in one of seven abstracts sponsored by United Therapeutics at the conference.

  • United Therapeutics Corporation To Report Third Quarter 2020 Financial Results Before The Market Opens On Wednesday, October 28, 2020
    PR Newswire

    United Therapeutics Corporation To Report Third Quarter 2020 Financial Results Before The Market Opens On Wednesday, October 28, 2020

    United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2020 financial results before the market opens on Wednesday, October 28, 2020.

  • United Therapeutics to Present New Tyvaso® Clinical and Treprostinil Real-World Data at CHEST Annual Meeting 2020
    PR Newswire

    United Therapeutics to Present New Tyvaso® Clinical and Treprostinil Real-World Data at CHEST Annual Meeting 2020

    United Therapeutics Corporation (Nasdaq: UTHR) today announced it will present clinical trial data on Tyvaso® (treprostinil) Inhalation Solution in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) at CHEST 2020, the annual meeting of the American College of Chest Physicians, which will be held on October 18-21. The presentation will include data from the phase 3 INCREASE study of Tyvaso in patients with PH-ILD, which included an evaluation of the impact of Tyvaso on parameters on lung function measured by patients' forced vital capacity. Additionally, data will be presented on the Orenitram® ADAPT registry, the utilization of parenteral prostacyclin therapy prior to death among Medicare patients with pulmonary arterial hypertension (PAH), and the psychological impact of living with PAH.